Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Updates in lymph node and skin pathology of adult T-cell leukemia/lymphoma, biomarkers, and beyond.

Adkins BD, Ramos JC, Bliss-Moreau M, Gru AA.

Semin Diagn Pathol. 2019 Dec 20. pii: S0740-2570(19)30114-5. doi: 10.1053/j.semdp.2019.12.006. [Epub ahead of print] Review.

PMID:
31889601
2.

Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.

Speir M, Nowell CJ, Chen AA, O'Donnell JA, Shamie IS, Lakin PR, D'Cruz AA, Braun RO, Babon JJ, Lewis RS, Bliss-Moreau M, Shlomovitz I, Wang S, Cengia LH, Stoica AI, Hakem R, Kelliher MA, O'Reilly LA, Patsiouras H, Lawlor KE, Weller E, Lewis NE, Roberts AW, Gerlic M, Croker BA.

Nat Immunol. 2020 Jan;21(1):54-64. doi: 10.1038/s41590-019-0550-7. Epub 2019 Dec 9.

PMID:
31819256
3.

Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics.

Hanlon K, Thompson A, Pantano L, Hutchinson JN, Al-Obeidi A, Wang S, Bliss-Moreau M, Helble J, Alexe G, Stegmaier K, Bauer DE, Croker BA.

Cancer Genet. 2019 Sep;237:69-77. doi: 10.1016/j.cancergen.2019.06.003. Epub 2019 Jun 12.

PMID:
31447068
4.

The pseudokinase MLKL activates PAD4-dependent NET formation in necroptotic neutrophils.

D'Cruz AA, Speir M, Bliss-Moreau M, Dietrich S, Wang S, Chen AA, Gavillet M, Al-Obeidi A, Lawlor KE, Vince JE, Kelliher MA, Hakem R, Pasparakis M, Williams DA, Ericsson M, Croker BA.

Sci Signal. 2018 Sep 4;11(546). pii: eaao1716. doi: 10.1126/scisignal.aao1716.

5.

A motive for killing: effector functions of regulated lytic cell death.

Bliss-Moreau M, Chen AA, D'Cruz AA, Croker BA.

Immunol Cell Biol. 2017 Feb;95(2):146-151. doi: 10.1038/icb.2016.113. Epub 2016 Nov 9. Review.

6.

Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.

Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC.

Oncotarget. 2015 Apr 10;6(10):8062-70.

7.

Identification of p38β as a therapeutic target for the treatment of Sézary syndrome.

Bliss-Moreau M, Coarfa C, Gunaratne PH, Guitart J, Krett NL, Rosen ST.

J Invest Dermatol. 2015 Feb;135(2):599-608. doi: 10.1038/jid.2014.367. Epub 2014 Aug 22.

8.

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD.

Cell. 2012 Aug 3;150(3):575-89. doi: 10.1016/j.cell.2012.06.032.

9.

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD.

J Clin Invest. 2012 Mar;122(3):948-62. doi: 10.1172/JCI60455. Epub 2012 Feb 22.

Supplemental Content

Loading ...
Support Center